Obesity is a profound public health issue, associated with increased mortality and risk for multiple diseases, including cardiovascular disease, diabetes, musculoskeletal disorders, and cancer. Weight loss in obese individuals reduces many of these risk factors, but weight loss and maintenance can be extremely difficult. Clearly, developing new approaches to treat obesity is an important goal, and is a key component of the Strategic Plan for NIH Obesity Research. A possible novel mechanism for treating obesity is activation of the a7 nicotinic cholinergic receptor. Nicotine's association with reduced body weight, and its ability to suppress appetite, increase energy expenditure and alter feeding patterns is well established. Recent evidence suggests that the a7 nicotinic receptor may play a particularly prominent role in these effects. Recent findings by our group separately examining the neuronal mechanisms of food intake behavior in non-mentally ill subjects and the neurobiology of nicotinic cholinergic dysfunction in schizophrenia unexpectedly have converged, showing that some of the same brain intrinsic network components that are overactive in obese individuals are down-modulated by an a7 nicotinic receptor agonist in patients. Given these effects, we recently conducted an initial study of the effect of the a7 nicotinic receptor partial agonist 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A) on weight, appetite and neuronal measures of the response to visual food cues in patients. These measures were an add- on outcome of a study designed to examine drug effects on cognition. Compared to placebo, DMXB-A was associated with significant weight loss and a reduction in hunger and appetite. Neuronally, DMXB-A was associated with alterations in the same brain regions we previously found to be involved in the response to food intake in lean compared to obese-prone individuals. We also found that the DMXB-A-associated change in insula response to food cues was related to weight change. Considering these preliminary results, and emerging evidence from animal studies, activation of a7 nicotinic receptors may be a novel mechanism to alter neuronal processes of food intake behavior and improve weight management in overweight/obese individuals in the general population. The overall goal of this application is to understand the effects of an a7 nicotinic receptor partial agonist on neuronal, physiological, and behavioral mechanisms of obesity in the general population. It is hoped that results of this study will inform our knowledge of nicotinic cholinergic involvement in obesity, potentially leading to novel treatment strategies to address a critical problem that negatively impacts health and quality of life.

Public Health Relevance

Obesity is a significant public health concern associated with an overall increased risk of mortality and risk of coronary heart disease and hypertension. This proposal investigates the neuronal, physiological, and behavioral effects of an a7 nicotinic agonist as a possible novel mechanism to treat obesity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK103691-04
Application #
9520032
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Stoeckel, Luke
Project Start
2015-08-06
Project End
2020-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Psychiatry
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Legget, Kristina T; Cornier, Marc-Andre; Bessesen, Daniel H et al. (2018) Greater Reward-Related Neuronal Response to Hedonic Foods in Women Compared with Men. Obesity (Silver Spring) 26:362-367
Tregellas, Jason R; Smucny, Jason; Rojas, Donald C et al. (2018) Predicting academic career outcomes by predoctoral publication record. PeerJ 6:e5707
Smucny, Jason; Tregellas, Jason R (2017) Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging. J Psychopharmacol 31:801-811
Smucny, Jason; Wylie, Korey P; Kronberg, Eugene et al. (2017) Nicotinic modulation of salience network connectivity and centrality in schizophrenia. J Psychiatr Res 89:85-96
Shapiro, Allison L B; Sauder, Katherine A; Tregellas, Jason R et al. (2017) Exposure to maternal diabetes in utero and offspring eating behavior: The EPOCH study. Appetite 116:610-615
Legget, Kristina T; Wylie, Korey P; Cornier, Marc-Andre et al. (2016) Exercise-related changes in between-network connectivity in overweight/obese adults. Physiol Behav 158:60-7
Wylie, Korey P; Smucny, Jason; Legget, Kristina T et al. (2016) Targeting Functional Biomarkers in Schizophrenia with Neuroimaging. Curr Pharm Des 22:2117-23
Smucny, Jason; Olincy, Ann; Rojas, Donald C et al. (2016) Neuronal effects of nicotine during auditory selective attention in schizophrenia. Hum Brain Mapp 37:410-21
Norris, Scott A; Jinnah, H A; Espay, Alberto J et al. (2016) Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord 31:1874-1882
Smucny, Jason; Olincy, Ann; Tregellas, Jason R (2016) Nicotine restores functional connectivity of the ventral attention network in schizophrenia. Neuropharmacology 108:144-51

Showing the most recent 10 out of 13 publications